Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Controlled Study Investigating the Combination of PD-1 Inhibitors With Local Therapy Administered at Distinct Treatment Timings Among Patients With Oligometastatic Esophageal Squamous Cell Carcinoma

NCT07697859 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07697859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07697859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Controlled Study Investigating the Combination of PD-1 Inhibitors With Local Therapy Administered at Distinct Treatment Timings Among Patients With Oligometastatic Esophageal Squamous Cell Carcinoma
Lead sponsor
Fudan University
Phase
Observational
Overall status
Recruiting
Start date
July 15, 2026
Completion date
July 15, 2031
Enrollment
354 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma (escc)